Physician profile
Dan Musat
NPI 1972767192
$27,452.59
in general payments reported to CMS, 2019-2025
26 companies · $3,727 in 2025
The $3,727 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,122 · 2020: $2,029 · 2021: $4,476 · 2022: $3,669 · 2023: $2,746 · 2024: $4,684 · 2025: $3,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,274 · Travel and Lodging: $3,508 · Consulting Fee: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,273.89 |
| Travel and Lodging | $3,507.69 |
| Consulting Fee | $2,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,104.60 | 2019-2025 | Rhythmia Mapping System, Watchman Flx, Farapulse |
| Medtronic, INC. | $5,065.85 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Baylis Medical Company INC | $4,009.38 | 2019 | |
| Altathera Pharmaceuticals LLC | $2,846.46 | 2021-2024 | Sotalol Hydrochloride |
| Philips North America LLC | $2,424.53 | 2019-2024 | (Am5) Lead Management |
| Abbott Laboratories | $1,486.26 | 2019-2025 | Aveir, Cardiomems |
| Janssen Research & Development, LLC | $1,310.94 | 2023 | |
| Zoll Respicardia, INC. | $878.50 | 2019 | |
| Cardiva Medical, INC. | $668.78 | 2019-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Biosense Webster, INC. | $569.43 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Sentiar, INC. | $500.00 | 2025 | Commandep |
| Preventice Services, LLC | $390.00 | 2021 | |
| Medtronic Vascular, INC. | $310.80 | 2020 | |
| Acutus Medical, INC. | $193.43 | 2021 | |
| Abiomed | $191.29 | 2023-2024 | Impella |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $114.88 | 2019-2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $78.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $75.07 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.77 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.87 | 2019-2023 | Camzyos |
| Inspire Medical Systems, INC. | $28.30 | 2023 | Inspire |
| Amgen INC. | $27.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.97 | 2023 | |
| Pfizer INC. | $17.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Musat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.